Factors Modifying Drug Action (Age, Weight, Genetics)

Introduction / Overview

Variability in drug response is a fundamental challenge in clinical pharmacology. Patient‑specific factors such as age, body mass, and genetic makeup shape how a medication is absorbed, distributed, metabolized, and excreted, and ultimately influence therapeutic efficacy and toxicity. Understanding these determinants is essential for optimizing dosing regimens and improving patient safety.

Learning Objectives

• Recognise how age‑related physiological changes affect pharmacokinetics and pharmacodynamics.
• Describe the influence of body weight and composition on drug distribution and clearance.
• Explain the impact of common pharmacogenetic polymorphisms on drug metabolism and response.
• Apply knowledge of these factors to adjust dosing in special populations.
• Identify potential drug–drug interactions that are amplified by age, weight, or genetic variants.

Classification

Factors modifying drug action are often grouped according to the dimension of patient variability they represent:

1. Age‑Related Factors – encompassing developmental pharmacology in pediatrics and gerontological changes in the elderly.
2. Weight and Body Composition – including lean body mass, adiposity, and the influence of obesity or cachexia.
3. Genetic Polymorphisms – primarily focusing on enzymes (CYP450), transporters (P‑gp, OCTs), and receptors (β‑adrenergic, muscarinic).

These categories intersect; for instance, an elderly obese patient may simultaneously exhibit age‑related renal decline and altered adipose distribution, complicating dose selection.

Mechanism of Action

Age‑Related Mechanistic Considerations

In neonates and infants, organ immaturity results in lower hepatic enzyme activity and reduced renal glomerular filtration. Consequently, drugs that rely on phase I metabolism or renal excretion may accumulate, altering receptor occupancy. In older adults, decreased cardiac output and peripheral perfusion can attenuate drug delivery to target tissues, while increased plasma protein binding in certain conditions may alter free drug concentration at receptors.

Weight‑Related Mechanistic Considerations

Body mass influences volume of distribution (Vd). Lipophilic drugs preferentially partition into adipose tissue, increasing Vd in obesity; hydrophilic agents may have reduced Vd due to limited extracellular fluid expansion. Changes in adipose versus lean mass can modify the amount of drug available to interact with receptors and transporters.

Genetic Mechanistic Considerations

Polymorphisms in cytochrome P450 enzymes (e.g., CYP2D6, CYP2C19) can render individuals poor, intermediate, extensive, or ultra‑rapid metabolizers, thereby affecting the concentration of active or toxic metabolites at the receptor site. Transporter variants such as ABCB1 (P‑gp) influence drug penetration across blood–brain and blood–testis barriers, while receptor polymorphisms may alter binding affinity and downstream signaling.

Pharmacokinetics

Absorption

Age influences gastric pH, motility, and mucosal integrity; infants exhibit lower gastric acidity, potentially reducing absorption of weak bases, whereas elderly patients may have delayed gastric emptying. Weight has limited direct impact on absorption, yet obesity can alter gastric surface area and transit time. Genetic factors may affect enteric transporters (e.g., SLC22A1), thereby modulating absorption efficiency.

Distribution

In children, higher total body water and lower plasma protein binding increase the Vd of hydrophilic drugs. In the elderly, decreased total body water and increased adiposity shift Vd of lipophilic agents. Obese adults may exhibit markedly expanded Vd for lipophilic drugs, necessitating dose adjustments. Genetic variants in albumin or alpha‑1‑acid glycoprotein can alter protein binding, affecting free drug levels.

Metabolism

Phase I and phase II enzymatic activity evolves across the lifespan. Newborns display diminished CYP3A4 and CYP2C9 activity, while older adults may experience reduced oxidative capacity. Obesity can induce or inhibit certain CYP enzymes, affecting drug clearance. Pharmacogenetic polymorphisms are the most significant determinant of metabolic rate for many drugs; for example, CYP2D6 poor metabolizers may require lower doses of tricyclic antidepressants to avoid toxicity.

Excretion

Renal clearance declines with age due to reduced glomerular filtration rate (GFR) and tubular secretion. Obesity may initially increase GFR but can lead to hyperfiltration injury over time. Genetic variations in renal transporters (e.g., SLC22A6, SLC22A8) can modify drug excretion profiles. Adjustments are often guided by estimated creatinine clearance or cystatin C measurements.

Half‑Life and Dosing Considerations

The elimination half‑life is a composite of clearance and Vd. Age and weight changes can extend half‑life, necessitating prolonged dosing intervals, while genetic rapid metabolism may shorten it, warranting more frequent dosing. Therapeutic drug monitoring is particularly valuable in patients with multiple modifying factors.

Therapeutic Uses / Clinical Applications

Commonly prescribed drugs whose pharmacokinetics are notably influenced by age, weight, or genetics include:

• Opioids – Metabolism via CYP2D6 and CYP3A4; dose adjustments for pediatric, elderly, and obese patients.
• Anticoagulants – Warfarin’s narrow therapeutic index is affected by CYP2C9 polymorphisms and age‑related vitamin K metabolism.
• Antiepileptics – Phenobarbital and carbamazepine undergo induction of hepatic enzymes, with dose modifications for age and body mass.
• Beta‑blockers – Hydrophilic agents (e.g., atenolol) exhibit altered clearance in renal impairment, common in elderly and obese individuals.

Off‑label uses often require careful consideration of these factors; for instance, the use of clozapine in children demands monitoring for hypersensitivity reactions that can be exacerbated by genetic predispositions.

Adverse Effects

Common Side Effects

Age‑associated changes often lead to increased sensitivity to central nervous system depressants. Obesity can predispose to respiratory complications with sedatives. Genetic variants may predispose individuals to hypersensitivity or increased toxicity; for example, HLA‑B*1502 carriers are at higher risk of carbamazepine‑induced Stevens–Johnson syndrome.

Serious / Rare Adverse Reactions

Severe hepatotoxicity may occur in infants receiving valproate due to immature detoxification pathways. Elderly patients on NSAIDs face heightened risk of gastrointestinal bleeding because of age‑related platelet dysfunction. Genetic defects in drug transporters can lead to central nervous system accumulation and neurotoxicity.

Black Box Warnings

Many drugs that are metabolized by enzymes with common polymorphisms carry black box warnings, such as the risk of severe cutaneous adverse reactions with carbamazepine in specific ethnic groups. The presence of such warnings underscores the necessity of evaluating genetic background before initiating therapy.

Drug Interactions

Major Drug‑Drug Interactions

Polypharmacy is common in the elderly, and many drugs share metabolic pathways. For instance, co‑administration of fluoxetine and warfarin can potentiate bleeding risk through inhibition of CYP2C9. Obesity may alter the pharmacokinetics of drug combinations by changing Vd and clearance, leading to unexpected interactions.

Contraindications

Contraindicated combinations often involve agents that share the same transporter or enzyme system, resulting in accumulation. For example, combining two CYP2D6 inhibitors in a poor metabolizer can precipitate severe toxicity. Age and weight must be considered when determining contraindications; a drug safe in a healthy adult may be hazardous in a frail elderly patient.

Special Considerations

Pregnancy / Lact

Physiological changes in pregnancy (increased plasma volume, altered enzyme activity) can reduce drug exposure. Weight gain during pregnancy affects Vd, especially for lipophilic drugs. Lactation may transfer drugs into breast milk; genetics influencing milk‑to‑plasma ratios can modify infant exposure.

Pediatric / Geriatric Considerations

In pediatrics, dosing is often weight‑based, but maturation of metabolic enzymes requires age‑specific adjustments. Geriatric patients, particularly those with reduced renal or hepatic function, may require dose reductions or extended intervals. Pharmacogenetic testing can aid in individualizing therapy in both age groups.

Renal / Hepatic Impairment

Renal impairment leads to decreased clearance of renally excreted drugs; dose reduction equations (e.g., Cockcroft‑Gault, MDRD) are essential. Hepatic impairment reduces capacity for phase I and II metabolism; drugs with high hepatic extraction ratios are especially affected. In both scenarios, genetic variations can compound impairment effects, necessitating careful monitoring.

Summary / Key Points

• Age, weight, and genetics independently and synergistically modify drug pharmacokinetics and pharmacodynamics.
• Physiologic changes in neonates, children, elderly, patients alter absorption, distribution, metabolism, and excretion.
• Common pharmacogenetic polymorphisms in CYP450 enzymes and transporters dictate individual metabolic capacity and drug disposition.
• Dosing strategies must incorporate age‑specific organ function, body composition, and genetic testing when available.
• Therapeutic drug monitoring, dose adjustments, and vigilant assessment of drug interactions are critical for safe pharmacotherapy in variable patient populations.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
5. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
8. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.